Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022

On April 11, 2022 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported its co-authorship of a study with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to be presented during the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 from April 8-13, 2022 (Press release, Personalis, APR 11, 2022, View Source [SID1234611996]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Working with Merck KGaA, Darmstadt, Germany, and leveraging the combination of transcriptome and exome-based data generated by the ImmunoID NeXT Platform, we were able to explore promising, integrative approaches to complementing the previously demonstrated classification method for colorectal cancer. We are excited to see how this collaboration further unfolds," said Richard Chen, MD, chief medical officer and SVP of R&D for Personalis.

Details of the poster are as follows:

Title: Comprehensive next generation sequencing profiling in combination with transcriptomic-based tumor molecular subtyping and harmonized TMB calculation using paired specimens from late-stage CRC patients (Poster 5743)

Session Category: Molecular/Cellular Biology and Genetics

Session Title: Genomics

Overview: This study reaffirms existing RNA-seq based molecular subtyping methods in late-stage CRC. Novel integrative methods are introduced which extend RNA-sequencing based subtyping by incorporating DNA-sequencing based mutation profiles, revealing potential integrated methods for subtype identification. This approach may be further investigated in larger cohorts, and by associating subtypes with other characteristics such as tumor laterality.